1 búsqueda de la palabra clave 'Alkylating agents'

Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions / Luis Vicente Syro Moreno  

Público ISBD Título : Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents  chemotherapy  DNA repair  neoplasms  neuroendocrine tumors  O(6)-Methylguanine-DNA Methyltransferase  pituitary  temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163 Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions [documento electrónico] / Luis Vicente Syro Moreno,  . - 2018. Obra : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents  chemotherapy  DNA repair  neoplasms  neuroendocrine tumors  O(6)-Methylguanine-DNA Methyltransferase  pituitary  temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000777	AC-2018-064	Archivo digital	Producción Científica	Artículos científicos	Disponible